| 前收盘价格 | 12.01 |
| 收盘价格 | 11.78 |
| 成交量 | 2,297,729 |
| 平均成交量 (3个月) | 820,656 |
| 市值 | 961,177,920 |
| 股市价格/股市净资产 (P/B) | 2.24 |
| 52周波幅 | |
| 利润日期 | 6 Feb 2025 - 10 Feb 2025 |
| 稀释每股收益 (EPS TTM) | -3.04 |
| 总债务/股东权益 (D/E MRQ) | 19.96% |
| 流动比率 (MRQ) | 10.11 |
| 营业现金流 (OCF TTM) | -181.10 M |
| 杠杆自由现金流 (LFCF TTM) | -113.40 M |
| 资产报酬率 (ROA TTM) | -27.07% |
| 股东权益报酬率 (ROE TTM) | -50.32% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Replimune Group, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
0.3
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.25 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.20% |
| 机构持股比例 | 92.17% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Braidwell Lp | 30 Sep 2024 | 3,070,837 |
| Omega Fund Management, Llc | 30 Sep 2024 | 2,461,319 |
| Boxer Capital, Llc | 30 Sep 2024 | 1,536,341 |
| Rtw Investments, Lp | 30 Sep 2024 | 1,133,787 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 19.00 (Jefferies, 52.12%) | 购买 |
| 中 | 17.50 (40.11%) | |
| 低 | 17.00 (HC Wainwright & Co., 36.11%) | 购买 |
| 17.00 (JP Morgan, 36.11%) | 购买 | |
| 平均值 | 17.75 (42.11%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 13.53 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Jefferies | 04 Dec 2024 | 19.00 (52.12%) | 购买 | 13.17 |
| BMO Capital | 22 Nov 2024 | 18.00 (44.12%) | 购买 | 14.93 |
| HC Wainwright & Co. | 22 Nov 2024 | 17.00 (36.11%) | 购买 | 14.93 |
| 12 Nov 2024 | 17.00 (36.11%) | 购买 | 12.19 | |
| JP Morgan | 24 Sep 2024 | 17.00 (36.11%) | 购买 | 11.07 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合